As part of the agreement Eusa will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex. GSK will fund and conduct all future development, production and commercialization of the product. Eusa’s product, OP-R003, is said to be the first fully human anti-interleukin-6 antibody, with target indications in oncology and inflammatory diseases.
Brian McVeigh, GSK’s worldwide business development director of M&A Strategy and Transactions, said: “Interleukin-6 is increasingly recognized as an important biological target in a range of diseases, and consequently OP-R003 has great potential to meet a number of unmet medical needs.”